rezzayo Drug Patent Profile
✉ Email this page to a colleague
When do Rezzayo patents expire, and when can generic versions of Rezzayo launch?
Rezzayo is a drug marketed by Cidara Theraps and is included in one NDA. There are seven patents protecting this drug.
This drug has ninety-two patent family members in twenty-four countries.
The generic ingredient in REZZAYO is rezafungin acetate. One supplier is listed for this compound. Additional details are available on the rezafungin acetate profile page.
DrugPatentWatch® Generic Entry Outlook for Rezzayo
Rezzayo will be eligible for patent challenges on March 22, 2027. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be March 22, 2035. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
Summary for rezzayo
International Patents: | 92 |
US Patents: | 7 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Drug Prices: | Drug price information for rezzayo |
What excipients (inactive ingredients) are in rezzayo? | rezzayo excipients list |
DailyMed Link: | rezzayo at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for rezzayo
Generic Entry Date for rezzayo*:
Constraining patent/regulatory exclusivity:
GENERATING ANTIBIOTIC INCENTIVES NOW NDA:
Dosage:
POWDER;INTRAVENOUS |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Pharmacology for rezzayo
Drug Class | Echinocandin Antifungal |
Anatomical Therapeutic Chemical (ATC) Classes for rezzayo
US Patents and Regulatory Information for rezzayo
rezzayo is protected by seven US patents and four FDA Regulatory Exclusivities.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of rezzayo is ⤷ Try a Trial.
This potential generic entry date is based on GENERATING ANTIBIOTIC INCENTIVES NOW.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting rezzayo
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: TREATMENT OF CANDIDEMIA AND INVASIVE CANDIDIASIS WITH REZAFUNGIN BY INTRAVENOUS ADMINISTRATION
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: TREATMENT OF CANDIDEMIA AND INVASIVE CANDIDIASIS WITH REZAFUNGIN BY INTRAVENOUS ADMINISTRATION
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: TREATMENT OF CANDIDEMIA AND INVASIVE CANDIDIASIS WITH REZAFUNGIN BY INTRAVENOUS ADMINISTRATION
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: TREATMENT OF CANDIDEMIA AND INVASIVE CANDIDIASIS WITH REZAFUNGIN BY INTRAVENOUS ADMINISTRATION
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: TREATMENT OF CANDIDEMIA AND INVASIVE CANDIDIASIS WITH REZAFUNGIN BY INTRAVENOUS ADMINISTRATION
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: TREATMENT OF CANDIDEMIA AND INVASIVE CANDIDIASIS WITH REZAFUNGIN BY INTRAVENOUS ADMINISTRATION
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: TREATMENT OF CANDIDEMIA AND INVASIVE CANDIDIASIS WITH REZAFUNGIN BY INTRAVENOUS ADMINISTRATION
FDA Regulatory Exclusivity protecting rezzayo
FOR USE IN PATIENTS 18 YEARS OF AGE OR OLDER WHO HAVE LIMITED OR NO ALTERNATIVE OPTIONS FOR THE TREATMENT OF CANDIDEMIA AND INVASIVE CANDIDIASIS
Exclusivity Expiration: ⤷ Try a Trial
NEW CHEMICAL ENTITY
Exclusivity Expiration: ⤷ Try a Trial
GENERATING ANTIBIOTIC INCENTIVES NOW
Exclusivity Expiration: ⤷ Try a Trial
GENERATING ANTIBIOTIC INCENTIVES NOW
Exclusivity Expiration: ⤷ Try a Trial
International Patents for rezzayo
See the table below for patents covering rezzayo around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Cyprus | 1122786 | ⤷ Try a Trial | |
Lithuania | 2827710 | ⤷ Try a Trial | |
Israel | 234505 | תכשיר פרמצבטי המכיל תרכובת אצ'ינוקנדין ושימוש בתכשיר מיובש בהקפאה המכיל תרכובת אצ'ינוקנדין בהכנת תמיסה מימית לטיפול בזיהום פטריתי (A pharmaceutical composition comprising an echinocandin compound and use of a lyophilized composition comprising an echinocandin compound in the preparation of an aqueous solution for treating a fungal infection) | ⤷ Try a Trial |
Portugal | 3677252 | ⤷ Try a Trial | |
Hong Kong | 1206935 | 用於棘白菌素類化合物的給藥方案 (DOSING REGIMENS FOR ECHINOCANDIN CLASS COMPOUNDS) | ⤷ Try a Trial |
Serbia | 64862 | DOZNI REŽIMI ZA JEDINJENJA KLASE EHINOKANDINA (DOSING REGIMENS FOR ECHINOCANDIN CLASS COMPOUNDS) | ⤷ Try a Trial |
Canada | 2865791 | AGENTS ANTIFONGIQUES ET LEURS UTILISATIONS (ANTIFUNGAL AGENTS AND USES THEREOF) | ⤷ Try a Trial |
>Country | >Patent Number | >Title | >Estimated Expiration |